{"id":"statin-plus-niacin-er-laropiprant","safety":{"commonSideEffects":[{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL426559","moleculeType":"Small molecule","molecularWeight":"435.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Statins inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis and LDL levels. Niacin (nicotinic acid) increases HDL and decreases triglycerides through multiple mechanisms including inhibition of hepatic VLDL production. Laropiprant is a selective antagonist of the prostaglandin D2 receptor (DP1), which mitigates the vasodilatory flushing side effect commonly associated with niacin therapy.","oneSentence":"A combination therapy that lowers LDL cholesterol via statin action while niacin ER/laropiprant raises HDL cholesterol and reduces triglycerides, with laropiprant blocking prostaglandin D2 receptors to reduce niacin-induced flushing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:04.381Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia and cardiovascular risk reduction in patients requiring statin and niacin therapy"}]},"trialDetails":[{"nctId":"NCT01052311","phase":"PHASE4","title":"The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2010-07","conditions":"Coronary Artery Disease, Dyslipidemia","enrollment":8},{"nctId":"NCT00485758","phase":"PHASE3","title":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Diabetes Mellitus Type 2","enrollment":796},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1216},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":"Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus","enrollment":25673},{"nctId":"NCT01126073","phase":"PHASE4","title":"Niacin/Laropiprant and Endothelial Function","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2010-09","conditions":"Coronary Heart Disease","enrollment":60},{"nctId":"NCT01010516","phase":"PHASE4","title":"Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia","status":"UNKNOWN","sponsor":"University of Ioannina","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Statin plus niacin ER/laropiprant","genericName":"Statin plus niacin ER/laropiprant","companyName":"University of Ioannina","companyId":"university-of-ioannina","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination therapy that lowers LDL cholesterol via statin action while niacin ER/laropiprant raises HDL cholesterol and reduces triglycerides, with laropiprant blocking prostaglandin D2 receptors to reduce niacin-induced flushing. Used for Dyslipidemia and cardiovascular risk reduction in patients requiring statin and niacin therapy.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}